The present invention relates to methods for treating medical conditionsand/or disorders characterized by uncontrolledor abnormal expression of members of the IL1R3 signaling pathway such as IL-1.alpha., IL-I.beta., IL-33, IL-36, IL1RA and/or IL1R3, as well asvariants thereof. More specifically, the present invention relates to anti-IL1R3 antibodies for use in the treatment of an IL1R3-mediatedinflammatory condition and/or disorder in a subject. Such conditions anddisorders include but are not limited to inflammatory diseases,immune disorders, fibrotic disorders, eosinophilic disorders, infection, pain,a central nervous system disorder, an ophthalmologicdisorder, Hereditary Systemic Inflammatory Diseases, and Systemic and LocalInflammatory Diseases and cancer associated chronicinflammation.
